In a strategic move to expand its immunology pipeline, AbbVie has agreed to acquire Capstan Therapeutics in a deal worth up to US$2.1 B. The acquisition grants AbbVie full rights to CPTX2309, a Phase I in-vivo CAR-T candidate targeting CD19-expressing B cells, along with Capstan’s proprietary targeted lipid nanoparticle (tLNP) platform for RNA delivery. This platform enables direct reprogramming of immune cells within the body, offering a novel approach to treating autoimmune diseases. The deal strengthens AbbVie’s position in immunology and supports its long-term growth strategy as it navigates revenue pressures from Humira’s patent expiry.